- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Immune System
- Kidneys and Urinary System
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Pregnancy and Childbirth
- Public Health and Safety
- Sexual Health
- Skin, Hair and Nails
- Substance Abuse
- Surgery and Rehabilitation
Heart attack patients taken to PCI hospitals first treated faster
American Heart Association Meeting Report - Abstract 4
- Patients taken directly to a hospital equipped to treat heart attacks with percutaneous coronary intervention (PCI) received treatments an average of 31 minutes faster than patients first taken to a hospital without PCI capability and later transferred for treatment.
ATLANTA ― Heart attack patients in North Carolina who were rushed directly to hospitals equipped to do percutaneous coronary intervention (PCI) received treatment significantly faster than patients first taken to hospitals unequipped to perform PCI and then later transferred for treatment, according to research reported at the American Heart Association’s Quality of Care and Outcomes Research 2012 Scientific Sessions.
The study focused on the most serious form of heart attack, ST-elevation myocardial infarction (STEMI) . A STEMI typically involves complete blockage of the blood flow to the heart. Opening the blocked artery as quickly as possible is crucial to improving survival.
Physicians often use PCI, also known as angioplasty, to open blocked coronary arteries. A tiny balloon is inserted through a catheter, or tube, into the affected area. The balloon is inflated to widen the blocked areas. Physicians often combine the procedure with the insertion of a stent to help prop the artery open and decrease the chance of another blockage.
Opening the blockage with clot-busting drugs is used when timely access to PCI is not an option.
Many emergency medical services (EMS) guidelines for transporting STEMI patients recommend bypassing hospitals that can’t provide PCI and going to one that can.
“Until now, no well designed study had examined this recommendation,” said Emil L. Fosbol, M.D., Ph.D., the study’s first author and a research fellow at Duke University in Durham, N.C. “The only rationale we had was the sooner you get there, the better.”
The researchers reviewed North Carolina’s EMS records from June 2008 to September 2010 and linked these to a clinical registry of patients with STEMI. Of the 1,224 STEMI patients who met the study’s specifications, 765 (63 percent) went directly to a PCI-capable hospital (bypass group), and 479 (37 percent) stopped first at a non-PCI hospital (non-bypass group) before being transferred for a PCI procedure.
- The time from first medical contact (FMC) to artery-opening treatment — PCI or clot-busting drug — averaged 93 minutes for the bypass group and 124 minutes for the non-bypass group, a substantial time difference that could improve a STEMI patient’s chances of surviving.
- For patients who received only PCI, the time from FMC to PCI averaged 93 minutes for the bypass group and 161 minutes for the non-bypass arm.
- Patients in the bypass group were almost three times as likely to get treatment within guideline recommendations compared to the non-bypass group.
“PCI is contingent on getting the patient very quickly to a hospital with a catheter lab,” Fosbol said. “Our results suggest that when logistically feasible, EMS should transfer STEMI patients directly to the nearest PCI-capable hospital.”
Co-authors are Christopher Granger, M.D.; James Jollis, M.D.; Lisa Monk, M.D.; Li Lin, M.D.; Barbara Lytle, M.D.; Ying Xian, M.D.; Lee Garvey, M.D.; Greg Mears, M.D.; Claire M Corbett, M.D.; Eric D Peterson, M.D.; and Seth Glickman, M.D.
The American Heart Association-Pharmaceutical Roundtable and David and Stevie Spina funded the study. Additional disclosures are on the abstract.
The American Heart Association’s Mission: Lifeline®-STEMI program supports systems of care to improve emergency response and treatment by quickly getting patients to the facilities with the most appropriate care. Additionally, the American Heart Association’s Mission: Lifeline® Heart Attack Referring/Receiving Center Accreditation program recognizes hospitals for their ability to quickly and appropriately treat heart attack patients. Learn more at www.heart.org/myhospital .
Statements and conclusions of study authors presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding .
NR12 –1069 (QCOR12/Fosbol)
Additional resources are available in the right column.
For Media Inquiries: (214) 706-1173
Cathy Lewis: (214) 706-1324; email@example.com
Tagni McRae: (214) 706-1383; firstname.lastname@example.org
Julie Del Barto (broadcast): (214) 706-1330; email@example.com
For Public Inquiries: (800) AHA-USA1 (242-8721)